Form D · Biotechnology
Verix Health, Inc.
Philadelphia, PA · CIK 0001791772
Offering snapshot reported Oct 30, 2019 · SEC filing
- Reported sold
- $1.5M Offering amount: $8M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 7, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 30, 2019 | Initial | $1,499,996 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-352156
Series A Preferred Stock
Source: Form D, filed Oct 30, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Dishowitz | Director, Executive, Promoter |
| Aftab Kherani | Director |
| Doug Koo | Executive |
| Tony Natale | Director |
| Duke Rohlen | Director |
| Sasha Schrode | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3401 Grays Ferry Ave. Bldg 212 157
Philadelphia, PA, 19146
Philadelphia, PA, 19146